Jacques Raubenheimer

20PUBLICATIONS
61CO-AUTHORS
Public economics - publicly provided goodsGene and molecular therapyPeople with disabilityHypersonic propulsion and hypersonic aerothermodynamicsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 12, 2026
The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.

|May 15, 2026
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

|Aug 14, 2025
Toward Normalizing Inclusive Design by Uncovering Patient Experiences of a Web Portal in a Dental Hospital: Mixed Methods Study.

Adeola Bamgboje-Ayodele, Jacques Raubenheimer, Anna Paonne

|Jul 16, 2025
Treatment Persistence in Rheumatoid Arthritis Before and After Etanercept Biosimilar Introduction: A Nationwide Australian Real-World Study.

Chin Hang Yiu, Bella D Ianni, Richard O Day

|Jun 25, 2025
Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence.

Chin Hang Yiu, Grace Tsz Yan Yau, Zoi Hei Wong

|Jun 05, 2025
Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.

Ramya Padmavathy Radha Krishnan, Monika Dzidowska, Danni Zheng

Pageof 4

Frequent Collaborators

7 joint publications

Nick A Buckley

5 joint publications

Christine Y Lu

5 joint publications

Richard O Day

5 joint publications

Chin Hang Yiu